From the advent of clonal selection theory 1,2 to the present day, it has become increasingly clear that the adaptive immune response has, as its central unit, the expression of a single rearranged immuno globulin or TCR on each B or T cell. And that, in general, single cells are the operational units or 'quanta' of immunity. With respect to T lymphocytes, this means that understanding their role in immune responses requires comprehensive methods of interrogating the phe notypic and functional characteristics of individual T cells. In this regard, the use of flow cytometry for highthroughput analysis of individual T cells has been the gold standard for many years 3 . Gradual improvements in flow cytometry, which allow simultaneous assess ment of the expression of surface and intracellular markers 4 and the precise temporal patterns of cytokine expression by T cells [5] [6] [7] , have enabled studies on the relationships between Tcell phenotype and/or function and clinical status in a range of diseases [8] [9] [10] [11] [12] [13] [14] . The study of antigen specificity, however, is complicated by enormous variability and unpredictability in terms of the epitopes targeted by T cells in any given Tcell response, especially considering the highly polymorphic nature of the MHC, and the fact that intact pathogens typically encode a wide variety of potential Tcell epitopes 15 . Furthermore, as the breadth or number of epitopes targeted by the Tcell response can be important, especially in rapidly evolving viral infections [16] [17] [18] , and the phenotypes of T cells targeting different epitopes from the same pathogen can vary widely 19, 20 , it is important to be able to monitor recognition of numerous epitopes in the response to each pathogen. As a result, the number of parameters analyzed in any given experi ment has grown beyond the number of colors (12-15) available for fluorescencebased flow cytometry, making the latter type of analy sis more arduous and at times impossible. Recent developments in methods for analyzing antigenspecific T cells that extend these limits exploit multiplexing and singlecell mass spectrometry-based mass cytometry [20] [21] [22] [23] [24] . Other emerging technologies that promise to dra matically increase both the speed of obtaining information about Tcell responses and its depth include techniques enabling the analysis of singlecell mRNA transcripts 25, 26 .
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In addition, unlike most mouse models of immunological diseases, wherein the identity of the antigenic epitopes that drive disease initia tion and/or progression are known, the instances of human immuno logical diseases wherein the precise specificities of T cells involved are known remain relatively rare. Therefore, until precise antigenic epitope specificities can be determined, study of these human Tcell responses requires alternative approaches; none appear to be more powerful than highthroughput sequencing of TCR repertoires. Data gener ated by this approach are providing insights into Tcell selection and the nature of repertoire diversity in various Tcell subsets in normal and pathological circumstances 27, 28 . TCR sequencing approaches also allow the identification and tracking of TCR clonotypes or motifs involved in immune responses and various pathologies [29] [30] [31] . Moreover, highthroughput yeastdisplay approaches represent a way to identify peptide-MHC ligands that bind to these TCR clonotypes or motifs 32, 33 . These approaches hold promise for identifying relevant antigens for immune responses for which the antigens are currently completely unknown. For instance, identification of antigens targeted by T cells in patients with autoinflammatory diseases could facilitate the development of novel treatment options.
Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells r e v i e w
In this Review we discuss the advantages, disadvantages and com plementarity of these highdimensional approaches for the study of antigenspecific T cells. Common to each approach is the goal of understanding and/or exploiting the specificity of the T cell-mediated immune response to manipulate or predict outcomes of immunological diseases or vaccine responses. These recent technological advances seem poised to finally make possible the comprehensive analyses of Tcell responses.
Analyzing T-cell phenotypic and functional diversity Each individual αβ T cell expresses one of >10 14 different TCR hetero dimers 34 and each of these TCRs is specific for a very small fraction of possible self or foreign antigens presented in the context of an individual's MHC molecules (Fig. 1a) . Thus, in terms of diversity of antigen specificity alone, T cells are one of the most diverse cell sub sets in the body. Several approaches for analyzing this diversity exist, and each has advantages and disadvantages ( Table 1) .
Flow cytometry. Flow cytometry has been the leading method for measuring this diversity over the past three decades. The latest instruments are remarkably powerful, capable of analyzing and/or sorting cells based on up to ~18 cellular parameters at >10,000 cells per second 4 . Such highdimensional and highthroughput analy sis has revealed relationships between Tcell phenotype and/or function and the clinical status for a range of diseases. For instance, in several infectious disease settings, a correlation between patho gen control and the polyfunctionality (that is, the capacity to per form more than one effector function, such as producing more than one cytokine) of the corresponding antigenspecific T cells has been identified [8] [9] [10] [11] [12] [13] . As less simplistic relationships between disease status and antigenspecific Tcell phenotypic and/or functional status must also exist, a great deal of effort is being dedicated to developing com puter algorithms that can analyze and extract useful information from this otherwise impossibletounderstand, highdimensional flow cytometry data [35] [36] [37] [38] .
Human T cells are often segregated into four major categories based on surface markers that indicate their proliferative poten tial, cytotoxicity capacity and their ability to produce cytokines. They are the following: naive (CCR7 + CD45RA + ), central memory (CCR7 + CD45RA − ), effector memory (CCR7 − CD45RA − ) and termi nal effector (CCR7 − CD45RA + ) 39 . Although simple, useful and well accepted, it is clear that much more heterogeneity exists than is cap tured by these subdivisions. For instance, expression of all possible combinations of CD27, CD28, CD62L and CCR7 are also observed, yet the significance of all of these distinctions is not clear 40 . Also, even cells fitting the most strict definition of naive (CD45RA + CD 45RO − CD27 + CCR7 + CD62L + CD28 + ), yet expressing higher levels of CD95, interleukin 2 receptor subunitβ (IL2Rβ), CXCmotif 41 . T cells can also be classified by their functional capacities (e.g., to produce various cytokines and effec tor molecules), transcription factor expression profiles 42 , as well as markers indicative of their tissue trafficking potential 43 . Combined with antigen specificity, as discussed below, the number of parameters that can be clearly distinguished by even the latest fluorescent flow cytometers is insufficient for an integrated and comprehensive view of Tcell diversity.
Mass cytometry. The arrival of mass cytometry has allowed a quan tum leap in phenotypic and functional characterization of single T cells. The mass spectrometry-based flow cytometry method (CyTOF) uses isotopically purified heavy metal atoms, instead of fluorophores, as tags 44 . Whereas the number of parameters available to fluorescent flow cytometry is limited by broad spectral overlap lead ing to crosstalk between fluorescent channels, in CyTOF many more parameters (now ~40, and dozens more should be possible in the near future) can be distinguished. In addition, thanks to reduced crosstalk between channels due to accurate resolution of tags differing by as little as a single atomic mass unit, the analysis and interpretation of CyTOF data are greatly simplified 45 . In terms of sample throughput, however, mass cytometry is substantially slower (capable of analyzing ~500 cells per second) than fluorescence flow cytometry (up to tens of thousands of cells per second). Although reduced sample through put makes carrying out studies with large sample sizes or rare cells a challenge, using preenrichment strategies, such as Tcell purification methods or tetramer enrichment approaches as we have applied 20, 22 , makes it possible to analyze even extremely rare antigenspecific T cells. Masstag barcoding 46 can also alleviate the throughput prob lem by allowing a large number (up to 96 so far) of uniquely tagged (barcoded) samples to be analyzed simultaneously. After data acquisi tion, simple and effective software is available for deconvolution of each barcoded sample 47 . Although mass cytometry is far from a comprehensive 'proteomics' method, extending cellular analysis into 40 dimensions means that each cell can be parsed into one of 2 40 (~1 trillion) possible bins, allow ing cells to be classified in unprecedented detail. It also means that a wide variety of Tcell markers can be assessed simultaneously provid ing a view of the overall diversity of a sample of cells. We have used mass cytometry to broadly probe the relationship between the CD8 + Tcell phenotype, function and antigenspecificity by simultaneously assessing several markers of each. For example, after using some of the parameters available at the time to isolate single CD8 + T cells, we probed six different antigen specificities using peptide-MHC tetramers (discussed below; Fig. 1b ) and used the remaining 25 parameters to evaluate expression of 16 surface and 9 functional markers 22 . In that study, we chose the parameters and the timing of assess ment to maximize the amount of information obtained form each cell and to reveal variation. Nonetheless, a caveat of this approach is that only a snapshot of information from a single timepoint taken from a single blood sample is available for each cell. Accurately tracking the kinetics of cellular responses requires an ability to continuously monitor single cells (as described below for the kinetics of cytokine secretion and in references 5-7 ). As there is a great deal of interest in Tcell polyfunctionality as an index of the strength of an immune response, in the same study we took advantage of the large number of cellular parameters available to mass cytometry by assessing nine different functional capacities (eight cytokines and a marker of granular release, CD107), in popu lations of activated human CD8 + T cells. This gave us 512 (2 9 ) pos sible combinations, and we were able to observe at least 242 of these, indicating that a vast number of possible functional combinations can be expressed. Furthermore, by using MHC tetramers bearing influ enza, cytomegalovirus (CMV) and EpsteinBarr virus (EBV) epitopes together with these nine functional markers, we showed that T cells specific for each of the different viruses expressed partially overlap ping but distinct combinations of cytokines, ranging from 50 to 100 different combinations of cytokines observed. Although only a few antigen specificities have been analyzed in this manner so far, these results indicate that Tcell responses are far more complex than pre viously thought, at least for CD8 + T cells, and that they seem tailored to the particular pathogen 22 .
To integrate both phenotypic and functional capacities of the cells, we also combined all the measured information about each cell and per formed dimensionality reduction using principal component analysis (PCA). PCA uses weighted combinations of each of the measurements to create composite parameters that maximally represent the data with a minimal number of new parameters. This approach provides an unbi ased composite representation of the cellular diversity that incorporates both phenotypic and functional information. It also provides insights about how these markers, and different Tcell subsets, are related to each other (Fig. 1c,d ) 22 . However, the represented pattern depends heavily on the cellular markers chosen for the analysis and on the com position of the cells being analyzed. We anticipate that this and other challenges of analyzing highdimensional cellular data will improve as new computational methods are developed and their utilities compared for various applications 35 . For example, more sophisticated analogs of PCA that combine the measured parameters in a nonlinear fashion are capable of explaining more variation in fewer dimensions and should enable better resolution of Tcell diversity 38 (Fig. 1e) .
The advantages of both fluorescence and mass cytometry include their ability to accurately and sensitively quantify proteins at the indi vidual cell level in rapid succession (hundreds to tens of thousands per second). However, their dependence on the availability of reli able antibodies specific for each protein severely limits their utility for discovery of novel proteins of interest. Furthermore, though the number of channels continues to increase, even for mass cytometry the number of isotopes in the periodic table represents a hard cap on the number of probes possible by this approach. 
Single T-cell phenotyping and temporal analysis using microwells. Another important new technique was developed by Love and col leagues, who spread T cells onto slides engineered to contain 100,000 microwells, such that many wells are occupied by only a single cell [5] [6] [7] . These cells can then be stimulated and many potential cytokines ana lyzed using antibody capture. This system revealed something unique, which is that individual T cells typically make multiple cytokines, not necessarily at the same time but often sequentially over a span of several hours 14 . This temporal complexity is not captured in other systems and takes advantage of the unique ability of this system to analyze the output of the same cells over time, and in a very high throughput manner.
Single-cell transcription profiling. Many of the limitations of flow cytometry and mass cytometry will eventually be overcome through the use of singlecell gene transcription profiling. However, because copy numbers of mRNA can be as low as just a few copies per cell, singlecell gene expression analysis remains difficult and the data need to be interpreted carefully 48 . Nonetheless, after careful validation, higherthroughput (up to 96 cells at a time), singlecell, quantitative RTPCR systems are already allowing up to 96 mRNA transcripts to be analyzed in each cell in a quantitative fashion 25, 37, 49 ( Fig. 2) . Highlighting diversity in the abundance of cellular mRNA transcripts, this approach proved to be useful in distinguishing gene expression profiles of tetramerstained and sorted antigenspecific T cells responding to the same antigen in the context of different genebased vaccination 49 . Though it is a dramatic improvement over bulk analysis without singlecell resolution (Fig. 2) , the analysis of only 96 cells at a time severely limits the current applicability of this approach. We anticipate that implementation of barcoding based technologies (as discussed below) will gradually increase throughput and broaden the applicability of singlecell transcrip tional profiling. Also exciting is the emergence of singlecell RNA sequencing meth ods that allow genomewide mRNA transcript quantification 26, 48, 50 . The use of barcoded primers used to multiplex the analysis of a large number of cells in a single DNA sequencing reaction will surely broaden the utility of the singlecell transcriptomics approach 48 . Although it will always be important to evaluate cellular protein levels instead of relying solely on mRNA levels, accurate genomewide transcriptomic information from single cells, if of sufficient through put and sensitivity, will add insight to that gained using proteomic methods; transcriptomic information might also lead to markers that can then be analyzed by proteomic methods. That said, cytometry methods that directly evaluate Tcell antigen specificity by using peptide-MHC multimers will remain essential.
Characterizing T-cell antigen specificity Studies of human immunology are limited by the availability of cellular material, which is usually restricted to small volumes of blood. Furthermore, to varying extents, depending on the immune response of interest, responsive T cells often represent a very small minority of total blood lymphocytes. Thus, to achieve sufficient signal above the inherent noise of complex blood samples, one must restrict analysis to the relevant cells-ideally through identification of T cells specific for the antigen of interest. However, the precise antigen specificities of T cells are known for only a handful of immune responses. Without knowledge of precise antigenic epitopes, only indirect methods that rely on a cellular response to stimulation with whole antigen (e.g., prolifer ation, cytokine production, surface marker expression changes 8, [51] [52] [53] [54] [55] [56] ) can be used. Furthermore, in these approaches, the analysis is 'singleplex' in that each sample of cells can be interrogated with only a single antigen (or single mixture of antigens). Thus, epitope mapping is either very low resolution or requires large volumes of sample. Detecting rare, antigenspecific T cells is also problematic especially if any other cells in the sample are activated and contrib ute to background signal. Lastly, depending on the method of detec tion (unless highdimensional approaches are used), the phenotypic and/or functional profile of the antigenspecific T cells can be mark edly limited in depth and influenced in unpredictable ways by the stimulation used to identity them.
Improvements to methods enabling direct detection of antigen specific cells are overcoming each of these limitations. As a result of their cooperative binding and ability to specifically label antigen specific T cells (Fig. 1) , peptide-MHC tetramers (or multimers) are now widely used for directly identifying and characterizing antigen specific T cells 57, 58 . Several recent technical advances have made this approach especially practical, including (i) higherthroughput production of hundreds or thousands of tetramers from one batch CXCR4  IL16  CD5  CD109  SLAMF1  TBX21  SLAMF5  TNFRSF9  FASLG  TNF  IFNg  IL2  ICOS  IL10  IL2Ra  CD3d  CD48  IL6ST  CD154  IL7R  CD69 (ii) detection of rare antigenspecific Tcell populations using mag netic bead-based enrichment of antigenspecific cells labeled with the peptide-MHC tetramer, allowing the characterization of very rare T cells, even those in the naive Tcell repertoire 61, 62 ; (iii) probing of larger numbers of Tcell antigen specificities in a single sample using combinatorial staining approaches 23, 24, 63 . Most recently, we demonstrated an approach that incorporates each of these improvements and exploits mass cytometry 20 . In this approach >100 antigen specificities and >20 phenotypic or functional markers can be probed in a single blood or tissue sample (Fig. 3a-c) . We used this approach to simultaneously screen for, identify and pheno typically characterize rotavirus antigen-specific T cells in blood and intestinal lymphocyte samples from healthy human donors. Parallel analysis of T cells specific for a range of previously identified viral (and other) antigens provided 'landmarks' for classifying and defining the phenotypic profiles of the identified cells. Through this parallel analysis, and consistent with what had previously been observed for EBV 19 , we identified significant differences in the phenotypic prop erties of T cells targeting different epitopes derived from the same virus 20 (Fig. 3d,e) . Assuming that it will be possible to increase the number of Tcell specificities that can be probed simultaneously using this approach (reconstruction experiments show that even a thousand different specificities may be possible 20 ) and to apply it to study CD4 + T cells and MHC class II-restricted antigens (H. McGuire & M.M.D., unpublished data), we anticipate that this method will enable the rapid identification of antigens related to a wide range of pathologies cur rently characterized by poorly defined Tcell responses.
It is currently impossible to predict a priori which of the multi tude of possible Tcell epitopes will be targeted by a T cell-mediated immune response 15, 64 . An ability to probe >100 or possibly >1,000 candidate epitopes is helpful but alone will not solve this problem, especially for diseases where the range of possible antigens is too large. As we and others have demonstrated for rotavirus and several other viral pathogens (e.g., influenza virus, Dengue virus and HIV) 20, [65] [66] [67] [68] with relatively small genomes, epitope or MHC binding-prediction algorithms 69, 70 provide a means of narrowing the possibilities and have been applied with some success. However, even for these small genome pathogens, the number of candidate epitopes can be quite large when prediction stringencies are relaxed in an effort to avoid missing epitopes or when viruses with high mutation rates and sig nificant epitope variation are considered. Furthermore, binding prediction algorithms perform especially poorly for MHC alleles for which there is much less peptide binding data with which to train the algorithms 71 . Sometimes it can help to broadly map epitopes through cellular stimulation-based approaches or, in the case of MHC class II-restricted cells, tetramerguided epitope mapping 72 before narrow ing it down to the precise epitopes using peptide-MHC multimers. Another solution is to use careful transcript sequence analysis, as has been done for the identification of tumorspecific mutations encoding candidate tumor antigens, based on wholeexome sequencing 73 . For example, in one recent study, >400 candidate antigens were screened using combinatorial tetramer staining of tumorinfiltrating lympho cytes in a lymphnode metastases to identify a single dominant epitope from a melanoma patient 74 . Lastly, direct identification of MHC bound peptides through peptide elution 75, 76 and everimproving mass spectrometry/proteomicsbased peptide sequencing should provide more accurate means of identifying candidate epitopes for npg r e v i e w a range of applications 77, 78 . Although aided by the development of more sensitive and sophisticated peptideidentifying mass spectro meters 79 , this approach is still currently limited by the large number of antigenpresenting cells required and the associated bias against low abundance and lowaffinity peptide ligands. Thus, despite the ongoing improvements being made to Tcellepitope discovery methods, iden tification of antigens for a number of diseases, such as autoimmune and autoinflammatory diseases, remain elusive. In these cases, TCR sequencing-based approaches hold promise as a reliable means of tracking and understanding antigenspecific Tcell responses, even when the identities of the antigens are unknown.
Sequencing the TCR repertoire
The advent of inexpensive and massively parallel DNA sequencing has begun to affect Tcell analysis, starting with the pioneering work of Robins and colleagues 80 to understand the scope of the human TCRβ repertoire. From these studies, it was found that natural biases in VDJ recombination lead to an overrepresentation of common rearrangement events and a higherthanexpected frequency of such sequences common between different donors 81, 82 . However, the vast majority of unique TCR sequences are present at low frequencies, as would be expected from early estimates of possible TCR diversity 34 . Considering these data, estimates of TCRβ repertoire diversity in an individual are difficult to calculate, yet lower bounds for total TCRβ diversity in a healthy adult 27, 80 are ~3-4 × 10 6 , approximately consist ent with previous estimates 83 . Single TCR chain, deepsequencing studies have also shown that the clonal diversity of memory cells is greater than might be expected, with only a minority of memory Tcell clones clearly expanded 84 . TCR sequencing has also been applied to accurately measure the TCR repertoire diversity of responding Tcell populations in cancer 31 , during human herpes virus infection 30 , dur ing CMV or polyomavirus BK reactivation, or during acute allograft rejection 85 . This technique also holds promise for investigating the extent of changes in the TCR repertoire during aging 86 . This approach has also proven to be a very sensitive means of accurately detecting the presence of rare malignant T cells, such as in minimal residual disease in acute Tlymphoblastic leukemia 87 . Extending this approach, several higherthroughput means of obtaining endogenous pairs of TCRα and β sequences from individual cells are emerging (Fig. 4a) . These include singlecell mRNA capture and emulsion linkage RTPCR, as recently described for simultaneous sequencing of heavy and light chains of immunoglobulin in single B cells 88 ; singlecell barcoding, as has been used for singlecell mRNA sequencing 28, 48 ; and direct cellularemulsionlinkage PCR 89 . Each of these methods allows the sequencing of α and β or γ and δ TCR sequences from individual cells much more efficiently than current practice.
In terms of applications, an especially promising approach would be to use singlecell methodologies and barcoding to analyze antigen specific Tcell responses in the many cases where the major epitopes are unknown. A glimpse of the potential insights that can be gained with this approach is found in our recently published study of Tcell responses in patients with celiac disease 29 . In this disease, patients have a strong autoimmune response to gluten, which inflames the gut and causes serious discomfort and damage. In most cases, eat ing a glutenfree diet eliminates the symptoms. We monitored the npg r e v i e w peripheral blood lymphocytes of celiac patients who had ingested gluten for any unusual responses. What was expected based on the work of Sollid and colleagues 90 was that gliadin (a subset of gluten proteins)specific CD4 + T cells would be activated and then enter the circulatory system approximately six days after the first gluten exposure. However, we found that populations of CD8 + T cells and γδ T cells appeared (and disappeared) with the same kinetics, all express ing guthoming receptors. We then employed a singlecell TCR ampli fication method using a large panel of primers to show that both the CD8 + and γδ Tcell populations were highly enriched for particular sequences and that complementaritydetermining region 3 (CDR3) encoded by these sequences was shared between many of the patients. This implies that all three of these different types of T cells are recog nizing specific ligands in this disease and somehow coordinating their responses. It also shows that it is possible to analyze Tcell responses directly after particular immunological events (albeit with a time lag) from a blood sample and assess the clonality of the response. In this study and in an analogous study that identified oligoclonal, skin resident, Tcell populations responding to herpes virus infection 30 , one chain from each Tcell population (TCRα, β, γ or δ) was ana lyzed. However, it is also possible to amplify both chains from single T cells as described above (which we have done; unpublished data). Adapting this methodology to a highthroughput system of singlecell analysis, as has been done by Georgiou 88 and W. Robinson (Stanford University, Department of Medicine; personal communication) for plasmablasts, one could envisage a very powerful way to analyze Tcell responses to disease or vaccination, which is entirely independent of other methods and requires no knowledge of the major antigens, but can lead to them.
Obtaining antigen specificity from TCR sequences It would be ideal if highthroughput sequencing of enough TCR sequences could be used to computationally predict Tcell specifi city from a given TCR heterodimer sequence. This would solve many of the problems and challenges discussed in this Review. However, unfortunately, we do not anticipate this to be possible anytime soon. There are several reasons for this but all stem from the highly variable nature of each of the components of the TCRpeptideMHC com plex. Unlike the binding of short, linear peptides to MHC, which is mediated by relatively simple motifs and mostly predictable anchor residues 91 , the energetics of TCR binding to peptide-MHC rely on numerous, highly unpredictable contacts between the TCR and both the MHC and the antigenic peptide 92 , although peptide residues gen erally contribute more than the MHC residues 93 . Solving such a prob lem depends on overcoming the difficulties in the field of predicting proteinprotein interactions in general, a challenge even when there are highresolution structures for each 94, 95 . Furthermore, it is clear that such a problem has far from a unique solution for a given TCR. This is because TCRs generally have a great deal of flexibility in one or both of the CDR3 loops, which are the principal determinants of peptide specificity 96 ; this flexibility allows them to recognize many different peptides that may not share any sequence homology. For example, Garcia and colleagues solved the structures of one TCR binding to four structurally distinct peptide-MHC complexes; in each case, the CDR3s of the TCR adopted a different conformation 32 . Considering these observations together with the relatively ubiqui tous crossreactivity of TCRs to homologous peptides 97, 98 , one can conclude that most TCRs can likely recognize many different pep tides, and with very low affinities (~10,000 times lower than most affinitymatured antibodies, for example). This means the 'fit' between a TCR and a ligand is much less stringent and therefore substantially harder to model than the fit between an antibody and its cognate antigen. Thus, we are not optimistic about the possibility of being able to computationally predict TCR antigen specificity solely from sequence information, at least by some form of structural prediction. An alternative may be to identify specific sequence motifs that can be associated with particular antigen responses (as found for antibody sequences in Dengue fever virus infection 99 ). But for now we will have to rely on experimental approaches for identifying Tcell antigens based on cloned TCRs. Fortunately, some such approaches are already proving to be useful.
One general strategy for identifying antigens bound by a particular cloned TCR is to create libraries of cells (insect/baculovirus or yeast), each expressing a single peptide-MHC antigen that can be selected by staining with tetramerized soluble TCR proteins. For this approach, one needs to know the restricting element (e.g., the appropriate MHC allele) before addressing the even larger challenge of identifying the corresponding peptide epitope. The power of this approach can be illustrated by the identification of the peptide-MHC complex recog nized by the TCR expressed on the murine diabetogenic Tcell clone, BDC2.5. Insect cell display was used to identify several mimotopes (presumably irrelevant peptides also capable of stimulating these cells) 100, 101 that eventually aided in the identification of the true endogenous antigen. This case was made especially difficult by the abnormal MHC binding register of the pathogenic epitope, which was not found in any of the insect cell libraries 101 .
A possibly faster approach is to generate yeast display libraries restricted to sequences derived from the pathogen of interest, as was demonstrated for influenza virus-specific human leukocyte antigen DR (HLADR)restricted CD4 + T cells 102 . Extending this to large random libraries 89, 90 , one can construct yeast display libraries in which a large number (10 5 -10 7 ) of different peptides bound to a given MHC molecule can be expressed, and these libraries can then be screened with a particular TCR to identify ligands 32, 33 (Fig. 4b) . This system enabled identification of a number of interesting H2L d restricted ligands of welldescribed mouse Tcell receptor clones. These included an epitope with a sequence totally unrelated to the sequence of the original antigen; although it had a high affinity for the TCR, this epitope failed to trigger Tcell activation, apparently owing to an abnormal docking orientation 32 . Hits like this and other mimotopes may be difficult to distinguish from immunologically relevant epitopes by this approach. However, as demonstrated 101 , identification of a consensus sequence from the hits searched against sequence databases containing candidate antigens should help tre mendously to narrow down the possibilities especially in cases where the source of the antigen is totally unknown. From this, shortlisted candidates can be used as input for a tetramer panel or stimulation based studies of polyclonal Tcell populations from which the TCRs of interest have been identified. Thus, as largescale, yeastdisplay screening approaches continue to improve in throughput and depth, we are optimistic that many more elusive, diseaseassociated, Tcell antigens will be identified, possibly leading to novel therapeutics and/or diagnostics.
Conclusions
The complexity of Tcell responses to pathogens in outbred popula tions has, in most cases, severely limited their assessment. This has forced a reliance on highly constrained animal models, which cannot give us a complete picture of how the different types of T cells func tion during an actual disease or vaccine challenge. It has also greatly inhibited attempts to find Tcell correlates of protection in vaccine or epidemiological work. Fortunately, the technologies discussed here npg represent a tremendous advance in our ability to capture that com plexity, and thus we may finally have the tools we need to broadly assess Tcell responses in most situations and to understand their contributions to immunity in much more depth. We anticipate that these approaches will give us much better ways of evaluating new vaccines and immunotherapies in the very near future.
